Acute Respiratory Distress Syndrome News and Research RSS Feed - Acute Respiratory Distress Syndrome News and Research

Experts focus on key issues impeding delivery of cardiac care in resource-limited settings

Experts focus on key issues impeding delivery of cardiac care in resource-limited settings

Critical care is defined by life-threatening conditions, which require close evaluation, monitoring, and treatment by appropriately trained health professionals. Cardiovascular care bears these same requirements. [More]
CytoSorbents announces launch of International CytoSorb Treatment Registry

CytoSorbents announces launch of International CytoSorb Treatment Registry

CytoSorbents Corporation, a critical care immunotherapy company using blood purification to treat life-threatening conditions, announced the launch of its International CytoSorb Treatment Registry, established and managed by the Center of Clinical Trials at the University of Jena, Germany. [More]
Study reveals how stem cells work to improve lung function in ARDS

Study reveals how stem cells work to improve lung function in ARDS

A new study has revealed how stem cells work to improve lung function in acute respiratory distress syndrome (ARDS). [More]
Heavy drinkers at greater risk of developing pneumonia and ARDS

Heavy drinkers at greater risk of developing pneumonia and ARDS

Heavy drinking damages the body in many ways. In addition to liver failure, alcoholics are at a much greater risk of developing pneumonia and life threatening acute respiratory distress syndrome (ARDS), for which there is no treatment. [More]
New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014. [More]
New tool can help doctors identify patients at highest risk for respiratory failure after surgery

New tool can help doctors identify patients at highest risk for respiratory failure after surgery

A new prediction tool can help doctors better identify patients who are at highest risk for respiratory failure after surgery and therefore prevent the often deadly condition, suggest data from a large multi-center study published in the May issue of Anesthesiology. [More]
Study helps physicians better identify patients at risk of acute respiratory distress syndrome

Study helps physicians better identify patients at risk of acute respiratory distress syndrome

Acute respiratory distress syndrome is a leading cause of respiratory failure after surgery. Patients who develop the lung disorder postoperatively are at higher risk of dying in the hospital, and those who survive the syndrome may still bear its physical effects years later. [More]
Discovery Laboratories reports net loss of $11.7 million for fourth quarter 2013

Discovery Laboratories reports net loss of $11.7 million for fourth quarter 2013

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the fourth quarter ended December 31, 2013, as well as recent business updates. [More]
Study indicates some groups have specific genetic make-up that prevents from fighting off influenza

Study indicates some groups have specific genetic make-up that prevents from fighting off influenza

Research indicated that some Indigenous people such as in Alaska and Australia displayed limited immunity response to the effects of influenza. [More]
Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million. [More]
Discovery Labs submits IND application to start AEROSURF phase 2 clinical program

Discovery Labs submits IND application to start AEROSURF phase 2 clinical program

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that it has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate its AEROSURF phase 2 clinical program. [More]

FDA approves Discovery Lab’s updated product specifications for SURFAXIN lucinactant

Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS. [More]
Emerging H7N9 virus has potential to cause a pandemic

Emerging H7N9 virus has potential to cause a pandemic

A new study has found that a novel avian-origin H7N9 influenza A virus, which has recently emerged in humans, attaches moderately or abundantly to the epithelium of both the upper and lower respiratory tracts. [More]
Fixed-ratio transfusion protocol in trauma patients is feasible, but wastes blood plasma

Fixed-ratio transfusion protocol in trauma patients is feasible, but wastes blood plasma

The use of a 1:1:1 blood transfusion protocol in patients with severe trauma is feasible in hospitals, although it is associated with higher waste of plasma, according to a randomized trial published in CMAJ (Canadian Medical Association Journal). [More]
H7 influenza may spillover repeatedly into humans, say scientists

H7 influenza may spillover repeatedly into humans, say scientists

The H7N9 avian flu strain that emerged in China earlier this year has subsided for now, but it would be a mistake to be reassured by this apparent lull in infections. The virus has several highly unusual traits that paint a disquieting picture of a pathogen that may yet lead to a pandemic, according to lead scientists from the National Institute of Allergy and Infectious Diseases. [More]
Study describes radiologic findings in H7N9 pneumonia

Study describes radiologic findings in H7N9 pneumonia

H7N9 pneumonia is characterized by imaging findings that differentiate it from other types of pneumonia, including rapidly progressive changes in the lungs and pulmonary connective tissues, according to the first study to describe radiologic findings in the disease. The results are published online in the journal Radiology. [More]
Researchers identify novel biomarkers for predicting mortality in ICU patients

Researchers identify novel biomarkers for predicting mortality in ICU patients

A metabolic profile of intensive care unit patients based on biomarkers of four metabolites can be used to accurately predict mortality, according to a new study. [More]
Inflammation and epigenetics: an interview with Dr Belkina and Dr Denis, Boston University School of Medicine

Inflammation and epigenetics: an interview with Dr Belkina and Dr Denis, Boston University School of Medicine

Inflammation can be thought of as taking two major forms: acute or chronic. Acute inflammation, which can be painful, usually arises quickly and resolves quickly. It accompanies bacterial infections, traumatic injury and is useful to fight infections and promote healing. [More]
High-frequency oscillatory ventilation put on hold

High-frequency oscillatory ventilation put on hold

Findings from two trials suggest that high-frequency oscillatory ventilation does not help, and may even harm patients with acute respiratory distress syndrome. [More]
Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer. [More]